Overview

A Study to Examine the Safety, Pharmacokinetics and Pharmacodynamics of AMG 403 in Healthy Subject

Status:
Completed
Trial end date:
2006-03-01
Target enrollment:
Participant gender:
Summary
This study is to evaluate the safety of AMG 403 in healthy adult subjects. The study consists of a 21 day screening period followed by administration of the investigational product and up to 154 day evaluation period.
Phase:
Phase 1
Details
Lead Sponsor:
Amgen